142 related articles for article (PubMed ID: 9425229)
1. Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane.
Deguen B; Mérel P; Goutebroze L; Giovannini M; Reggio H; Arpin M; Thomas G
Hum Mol Genet; 1998 Feb; 7(2):217-26. PubMed ID: 9425229
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton.
Sainio M; Zhao F; Heiska L; Turunen O; den Bakker M; Zwarthoff E; Lutchman M; Rouleau GA; Jääskeläinen J; Vaheri A; Carpén O
J Cell Sci; 1997 Sep; 110 ( Pt 18)():2249-60. PubMed ID: 9378774
[TBL] [Abstract][Full Text] [Related]
3. Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain.
Brault E; Gautreau A; Lamarine M; Callebaut I; Thomas G; Goutebroze L
J Cell Sci; 2001 May; 114(Pt 10):1901-12. PubMed ID: 11329377
[TBL] [Abstract][Full Text] [Related]
4. Merlin differentially associates with the microtubule and actin cytoskeleton.
Xu HM; Gutmann DH
J Neurosci Res; 1998 Feb; 51(3):403-15. PubMed ID: 9486775
[TBL] [Abstract][Full Text] [Related]
5. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
[TBL] [Abstract][Full Text] [Related]
6. Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker.
Algrain M; Turunen O; Vaheri A; Louvard D; Arpin M
J Cell Biol; 1993 Jan; 120(1):129-39. PubMed ID: 8416983
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.
Stokowski RP; Cox DR
Am J Hum Genet; 2000 Mar; 66(3):873-91. PubMed ID: 10712203
[TBL] [Abstract][Full Text] [Related]
8. Schwannomin isoform-1 interacts with syntenin via PDZ domains.
Jannatipour M; Dion P; Khan S; Jindal H; Fan X; Laganière J; Chishti AH; Rouleau GA
J Biol Chem; 2001 Aug; 276(35):33093-100. PubMed ID: 11432873
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin.
Scoles DR; Huynh DP; Morcos PA; Coulsell ER; Robinson NG; Tamanoi F; Pulst SM
Nat Genet; 1998 Apr; 18(4):354-9. PubMed ID: 9537418
[TBL] [Abstract][Full Text] [Related]
10. Subcellular localization and expression pattern of the neurofibromatosis type 2 protein merlin/schwannomin.
Schmucker B; Ballhausen WG; Kressel M
Eur J Cell Biol; 1997 Jan; 72(1):46-53. PubMed ID: 9013725
[TBL] [Abstract][Full Text] [Related]
11. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin.
Grönholm M; Sainio M; Zhao F; Heiska L; Vaheri A; Carpén O
J Cell Sci; 1999 Mar; 112 ( Pt 6)():895-904. PubMed ID: 10036239
[TBL] [Abstract][Full Text] [Related]
12. Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells.
Scherer SS; Gutmann DH
J Neurosci Res; 1996 Dec; 46(5):595-605. PubMed ID: 8951671
[TBL] [Abstract][Full Text] [Related]
13. Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin.
Shaw RJ; McClatchey AI; Jacks T
Cell Growth Differ; 1998 Apr; 9(4):287-96. PubMed ID: 9563848
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the actin cytoskeleton in the regulation of serotonin transporter (SET) activity: possible mechanism underlying SET regulation by protein kinase C.
Sakai N; Kodama N; Ohmori S; Sasaki K; Saito N
Neurochem Int; 2000 Jun; 36(7):567-79. PubMed ID: 10771115
[TBL] [Abstract][Full Text] [Related]
15. Interdomain binding mediates tumor growth suppression by the NF2 gene product.
Sherman L; Xu HM; Geist RT; Saporito-Irwin S; Howells N; Ponta H; Herrlich P; Gutmann DH
Oncogene; 1997 Nov; 15(20):2505-9. PubMed ID: 9395247
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a cytoskeleton attachment domain at the N-terminus of the NF2 protein.
den Bakker MA; Riegman PH; Suurmeijer AP; Vissers CJ; Sainio M; Carpen O; Zwarthoff EC
J Neurosci Res; 2000 Dec; 62(6):764-71. PubMed ID: 11107160
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.
Goutebroze L; Brault E; Muchardt C; Camonis J; Thomas G
Mol Cell Biol; 2000 Mar; 20(5):1699-712. PubMed ID: 10669747
[TBL] [Abstract][Full Text] [Related]
18. Insights into a single rod-like helix in activated radixin required for membrane-cytoskeletal cross-linking.
Hoeflich KP; Tsukita S; Hicks L; Kay CM; Tsukita S; Ikura M
Biochemistry; 2003 Oct; 42(40):11634-41. PubMed ID: 14529273
[TBL] [Abstract][Full Text] [Related]
19. Activation of the tumor suppressor merlin modulates its interaction with lipid rafts.
Stickney JT; Bacon WC; Rojas M; Ratner N; Ip W
Cancer Res; 2004 Apr; 64(8):2717-24. PubMed ID: 15087385
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton.
den Bakker MA; Tascilar M; Riegman PH; Hekman AC; Boersma W; Janssen PJ; de Jong TA; Hendriks W; van der Kwast TH; Zwarthoff EC
Am J Pathol; 1995 Nov; 147(5):1339-49. PubMed ID: 7485397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
